Agree. Hard to rationalize the DSMB decision to continue as is with 2 doses, especially when Dr. J asked them that specific question. Maybe possible that the patients enrolled in the second half of the study are the ones who declined in the 3rd and 4th week which caused the study failure and they weren't able to see that at that time. Cytodyn should look into when the patients that failed leronlimab enrolled and who had the role of choosing the DSMD--especially regarding the rumored ties to Gilead.